Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, have helped UK-basedcell therapy developer Cell Medica raise £17m ($26.5m).

The Cancer Prevention and Research Institute of Texas has also offered $15.3m to back Cell Medica’s cancer immunotherapy technology licensed from Baylor College of Medicine.

Thomas Hecht, the former vice president of marketing in Europe for Amgen is becoming chairman and UK-based foundation the Wellcome Trust is converting its investment in the company into equity.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?